Secondary analysis of the phase 3 NeoTRIPaPDL1 trial (280 patients with high-risk TNBC, neoadjuvant carboplatin/nab-paclitaxel with or without atezolizumab): absence of tumour cells in early on-treatment biopsies strongly predicted pCR in both arms.
Secondary analysisn = 280
Dugo et al. Longitudinal transcriptomic profiling identifies predictors of response to neoadjuvant chemoimmunotherapy in triple-negative breast cancer: results from the NeoTRIPaPDL1 trial